A new study published in the Journal American Medical Association showed that patients with an Cystatin C based estimated ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Please provide your email address to receive an email when new articles are posted on . Rapid eGFR decline occurred in 23% of patients on high-intensity exercise. Meanwhile, rapid eGFR decline ...
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Results showed highest risks for CVD for low eGFR and ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
A cystatin C–based blood test may provide a more reliable way to monitor kidney function in children and young adults with SCD, a study found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results